SavedAdd your journal

Journals / İstanbul Journal of Pharmacy / 2020 / Cilt: 50 - Sayı: 3

Cytochrome P450 2A13 3375C>T gene polymorphism in a Turkish population

Zuhal UÇKUN ŞAHİNOĞULLARI
Pages
181–187
Publication Date
2020-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study can provide valuable data for further studies investigating the role of this polymorphism concerning the susceptibility to xenobiotics-induced toxic effects, including cancer, and may be used as a control group for such studies and also may contribute to toxicogenetic and epidemiological studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: The polymorphisms in genes encoding xenobiotic-metabolizing enzymes may change the metabolic activation of various xenobiotics and therefore may affect individuals’ susceptibility to xenobiotics-induced toxic effects.
📊
Key Findings & Data:Cytochrome P450 2A13 (CYP2A13) is an important CYP enzyme predominantly expressed in the human respiratory tract.
💡
Conclusion & Impact:Conclusion: This study can provide valuable data for further studies investigating the role of this polymorphism concerning the susceptibility to xenobiotics-induced toxic effects, including cancer, and may be used as a control group for such studies and also may contribute to toxicogenetic and epidemiological studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:CYP2A13 3375C>T · genetic polymorphism · Arg257Cys

Abstract

Background and Aims: The polymorphisms in genes encoding xenobiotic-metabolizing enzymes may change the metabolic activation of various xenobiotics and therefore may affect individuals’ susceptibility to xenobiotics-induced toxic effects. Cytochrome P450 2A13 (CYP2A13) is an important CYP enzyme predominantly expressed in the human respiratory tract. CYP2A13 metabolizes the xenobiotics and bioactivation of several carcinogens. The present study aimed to determine the allele and genotype frequencies of CYP2A13 3375C>T polymorphism in a Turkish population and also to compare the obtained results with those of various populations. Methods: CYP2A13 3375C>T polymorphism was determined in 93 healthy Turkish individuals using the polymerase chain reaction-restriction fragment length method. Results: The frequencies of CC, CT and TT genotypes were 89.2%, 9.7% and 1.1%, respectively. The frequencies of C and T alleles were 94.1% and 5.9%, respectively. The genotype frequencies did not deviate from the Hardy-Weinberg equilibrium. Significant differences were observed when comparing the results found with those of various populations, especially those of populations with black ancestry (excluding Tunisian). Conclusion: This study can provide valuable data for further studies investigating the role of this polymorphism concerning the susceptibility to xenobiotics-induced toxic effects, including cancer, and may be used as a control group for such studies and also may contribute to toxicogenetic and epidemiological studies.

🔖

Cite This Article

ŞAHİNOĞULLARI, Z. U. (2020). Cytochrome P450 2A13 3375C>T gene polymorphism in a Turkish population. İstanbul Journal of Pharmacy, Cilt: 50 - Sayı: 3, 181–187. https://ajindex.com/articles/676267

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Alzahrani, A. M., & Rajendran, P. (2020). The multifarious link between cytochrome P450s and cancer. Oxidative Medicine and Cellular Longevity, 2020:3028387. • Cauffiez, C., Pottier, N., Tournel, G., Lo-Guidice, J. M., Allorge, D., Chevalier, D., Migot-Nabias, F., Kenani, A., & Broly, F. (2005). CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations. Xenobiotica, 35(7), 661−669. • Cheng, X. Y., Chen, G. L., Zhang, W. X., Zhou, G., Wang, D., & Zhou, H. H. (2004). Arg257Cys polymorphism of CYP2A13 in a Chinese population. Clinica Chimica Acta, 343(1-2), 213−216. • D‘Agostino, J., Zhang, X., Wu, H., Ling, G., Wang, S., Zhang, Q.Y., Liu, F., & Ding, X. (2008). Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metabolism and Disposition, 36(11), 2316−2323. • Elfaki, I., Mir, R., Almutairi, F. M., & Duhier, F. M. A. (2018). Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pacific Journal of Cancer Prevention, 19(8), 2057−2070. • Fujieda, M., Yamazaki, H., Kiyotani, K., Muroi, A., Kunitoh, H., Dosaka- Akita, H., Sawamura, Y., & Kamataki, T. (2003). Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metabolism and Pharmacokinetics, 18(1), 86−90. • Fukami, T., Nakajima, M., Matsumoto, I., Zen, Y., Oda, M., & Yokoi, T. (2010). Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Science, 101(4), 1024−1028. • Fukami, T., Nakajima, M., Sakai, H., Katoh, M., & Yokoi, T. (2007). CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metabolism and Disposition, 35(3), 335–339. • Herr, D., Bettendorf, H., Denschlag, D., Keck, C., & Pietrowski, D. (2006). Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma. Archives of Gynecology and Obstetrics, 274(6), 367−371. • http-1: https://www.pharmvar.org/gene/CYP2A13. Accessed 10.04.2020. • http-2: https://www.internationalgenome.org/1000-genomesbrowsers/. Accessed 03.04.2020. • Jiang, J. H., Jia, W. H., Chen, H. K., Feng, B. J., Qin, H. D., Pan, Z. G., Shen, G. P., Huang, L. X., Feng, Q. S., Chen, L. Z., Lin, D. X., & Zeng, Y. X. (2004). Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population. Journal of Translational Medicine, 2(1), 24. • Kim, V., Yeom, S., Lee, Y.,